All In MedTech

Device Trial Radar · NCT06057051

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Sep 1, 2023

Primary completion

Aug 2025

Study completion Aug 2027

Sponsor

Lead sponsor
Glaukos CorporationPublic (GKOS)
Sponsor type
Industry
First posted
Sep 28, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Conditions

  • Glaucoma

Interventions

  • iStent InfiniteDevice

    iStent Infinite Trabecular Micro-Bypass System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from BaselineTime frame: 12 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaukos Investigator Site

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.